Benitec Biopharma Inc. (BNTC) stock
BNTCNasdaqPharmaceutical PreparationsFiscal year ends December 31
$8.15−0.39 (-4.57%)
Close on Nov 17, 2026Market cap $284.29MP/E –Yield –
Benitec Biopharma r&d expenses
Research and development expenses are spending on new products and technology.
Benitec Biopharma's R&D Expenses for the twelve months ending Jun 30, 2026 was $23.39M, up 27.6% year over year. For fiscal 2026 it was $23.39M, up 27.6% from the year before. The highest annual figure on record is $23.39M in fiscal 2026.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Jun 30, 2026 | $23.39M | +27.6% |
| FY2025 | Jun 30, 2025 | $18.33M | +17.4% |
| FY2024 | Jun 30, 2024 | $15.61M | +22.2% |
| FY2023 | Jun 30, 2023 | $12.77M | +13.3% |
| FY2022 | Jun 30, 2022 | $11.27M | +60.6% |
| FY2021 | Jun 30, 2021 | $7.02M | +133.9% |
| FY2020 | Jun 30, 2020 | $3.00M | -34.3% |
| FY2019 | Jun 30, 2019 | $4.57M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2026CQ2 2026 | Jun 30, 2026 | $7.89M | +175.1% |
| Q3 FY2026CQ1 2026 | Mar 31, 2026 | $6.30M | -3.0% |
| Q2 FY2026CQ4 2025 | Dec 31, 2025 | $5.83M | +8.3% |
| Q1 FY2026CQ3 2025 | Sep 30, 2025 | $3.37M | -6.0% |
| Q4 FY2025CQ2 2025 | Jun 30, 2025 | $2.87M | -18.4% |
| Q3 FY2025CQ1 2025 | Mar 31, 2025 | $6.50M | +153.1% |
| Q2 FY2025CQ4 2024 | Dec 31, 2024 | $5.39M | +5.5% |
| Q1 FY2025CQ3 2024 | Sep 30, 2024 | $3.59M | -19.1% |
| Q4 FY2024CQ2 2024 | Jun 30, 2024 | $3.51M | +10.2% |
| Q3 FY2024CQ1 2024 | Mar 31, 2024 | $2.57M | -19.0% |
| Q2 FY2024CQ4 2023 | Dec 31, 2023 | $5.10M | +35.7% |
| Q1 FY2024CQ3 2023 | Sep 30, 2023 | $4.43M | +66.5% |
| Q4 FY2023CQ2 2023 | Jun 30, 2023 | $3.19M | +0.3% |
| Q3 FY2023CQ1 2023 | Mar 31, 2023 | $3.17M | +45.9% |
| Q2 FY2023CQ4 2022 | Dec 31, 2022 | $3.76M | +19.5% |
| Q1 FY2023CQ3 2022 | Sep 30, 2022 | $2.66M | -4.3% |
| Q4 FY2022CQ2 2022 | Jun 30, 2022 | $3.18M | +36.9% |
| Q3 FY2022CQ1 2022 | Mar 31, 2022 | $2.17M | -21.3% |
| Q2 FY2022CQ4 2021 | Dec 31, 2021 | $3.15M | +169.3% |
| Q1 FY2022CQ3 2021 | Sep 30, 2021 | $2.78M | +259.2% |
| Q4 FY2021CQ2 2021 | Jun 30, 2021 | $2.32M | +156.1% |
| Q3 FY2021CQ1 2021 | Mar 31, 2021 | $2.76M | +242.6% |
| Q2 FY2021CQ4 2020 | Dec 31, 2020 | $1.17M | +95.0% |
| Q1 FY2021CQ3 2020 | Sep 30, 2020 | $774.00K | +83.0% |
| Q4 FY2020CQ2 2020 | Jun 30, 2020 | $906.00K | – |
| Q3 FY2020CQ1 2020 | Mar 31, 2020 | $805.00K | – |
| Q2 FY2020CQ4 2019 | Dec 31, 2019 | $599.00K | – |
| Q1 FY2020CQ3 2019 | Sep 30, 2019 | $423.00K | – |
See a number that looks wrong?